Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Mosunetuzumab-Polatuzumab Vedotin Combo Effective, Well Tolerated in R/R B-NHL

June 5th 2021

Two cases of cytokine release syndrome occurred during the first cycle of step-up dosing; however, both were considered non-severe and were treated without the need of tocilizumab, admission to the ICU or use of vasopressors.

Dr. Lunning on the Efficacy of Axi-Cel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

June 2nd 2021

Matthew Lunning, DO, discusses the efficacy of axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Loncastuximab Tesirine Provides Alternative for Broad Range of Patients With DLBCL

June 1st 2021

Loncastuximab tesirine-lpyl (Zynlonta) exhibited significant clinical activity, including impressive response rates with tolerable safety, as a single agent in adult patients with relapsed/refractory large B-cell lymphoma that failed prior established therapies.

New DLBCL Treatments Are Poised to Fill an Unmet Need for Patients in Challenging Settings

May 26th 2021

During a recent OncLive Peer Exchange®, a panel of lymphoma experts discussed tafasitamab-cxix, polatuzumab vedotin-piiq, and selinexor, and how and when they use them for their patients with diffuse large B-cell lymphoma.

FDA Accepts BLA for Ublituximab/Umbralisib in CLL and SLL

May 25th 2021

The FDA has accepted a biologics license application for ublituximab in combination with umbralisib in the treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia.

FDA Grants Priority Review to Zanubrutinib for Marginal Zone Lymphoma

May 19th 2021

The FDA has granted priority review to a supplemental new drug application for zanubrutinib as a treatment option for adult patients with marginal zone lymphoma who have previously received at least 1 anti-CD20–based therapy.

Loncastuximab Tesirine Showcases Substantial Antitumor Activity in Heavily Pretreated Relapsed/Refractory DLBCL

May 18th 2021

Loncastuximab tesirine-lypl has demonstrated significant antitumor activity with durable responses and an acceptable toxicity profile, when used as a monotherapy in heavily pretreated patients with relapsed or refractory diffuse large B-cell lymphoma.

FDA Lifts Partial Clinical Hold on Odronextamab Studies in Follicular Lymphoma and DLBCL

May 18th 2021

The FDA has lifted a partial clinical hold that had been placed on the enrollment of patients with follicular lymphoma and diffuse large B-cell lymphoma to monotherapy trials examining the bispecific antibody odronextamab.

Dr. Matasar on the Rationale for Combining Copanlisib and Rituximab in Indolent NHL

May 13th 2021

Matthew J. Matasar, MD, Memorial Sloan Kettering Cancer Center Bergen, discusses the rationale for combining copanlisib and rituximab in patients with indolent non-Hodgkin lymphoma.

High Pretreatment ctDNA Levels Correlate With Short Diagnosis-to-Treatment Intervals in DLBCL

May 12th 2021

Pretreatment circulating tumor DNA levels were found to more objectively measure disease burden compared with diagnosis-to-treatment intervals in patients with diffuse large B-cell lymphoma and can therefore be used to quantify and mitigate selection bias in prospective DLBCL clinical trials.

Rapid Readouts: Results from the Phase 3 CHRONOS-3 Trial for Relapsed iNHL

May 7th 2021

Tycel J. Phillips, MD, presents slides from the American Association for Cancer Research (AACR) Virtual Annual Meeting 2021 of results from the phase 3 CHRONOS-3 study of copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (iNHL).

Loncastuximab Tesirine-Ipyl Added to NCCN Guidelines for B-Cell Lymphomas

May 6th 2021

The recently FDA-approved loncastuximab tesirine-lpyl has been added to the latest National Comprehensive Cancer Network Clinical Practice Guidelines for B-cell lymphomas.

Dr. D’Angelo on Selecting CAR T-Cell Therapy or Transplantation in DLBCL

May 4th 2021

Christopher R. D’Angelo, MD, discusses factors that determine whether CAR T-cell therapy or autologous stem cell transplant should be used in patients with relapsed/refractory diffuse large B-cell lymphoma.

DPX-Survivac/Pembrolizumab Plus Cyclophosphamide to Be Examined in DLBCL

May 3rd 2021

Following feedback from the FDA, IMV Inc. and Merck have entered into an agreement to open a phase 2b clinical trial examining the combination of maveropepimut-S and pembrolizumab plus low-dose cyclophosphamide in patients with recurrent/refractory diffuse large B-cell lymphoma.

Phase 1/2 Studies Set the Stage for Targeted Combos in B-Cell Lymphomas

April 27th 2021

Although chemotherapy is not likely to lose its place in the frontline treatment of patients with B-cell lymphomas, encouraging data from early-phase studies evaluating the use of targeted agents in combination with and without chemotherapy are capturing the interest of investigators in the field.

Options for CAR-T Therapy in the Third-Line Setting

April 27th 2021

A key opinion leader in diffuse large B-cell lymphoma provides a historical perspective on third-line options for CAR T-cell therapy and shares insights on both clinical trial and real-world data.

Unmet Needs in Relapsed/Refractory DLBCL

April 27th 2021

An expert in hematology oncology, Amit Patel, BSc, MBBS, PhD, reviews the unmet needs for patients with relapsed/refractory diffuse large B-cell lymphoma.

FDA Approves Loncastuximab Tesirine for Relapsed/Refractory Large B-Cell Lymphoma

April 23rd 2021

The FDA has granted an accelerated approval to loncastuximab tesirine (Zynlonta) for the treatment of adult patients with relapsed/refractory large B-cell lymphoma following 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma.

Pivotal Trials Address Pressing Questions With CAR T-Cell Therapy in B-Cell Lymphoma

April 22nd 2021

Nilanjan Ghosh MD, PhD, highlights progress made with CAR T-cell therapies in B-cell lymphoma and some ongoing trials generating interest in the field.

Glofitamab Demonstrates Durable Responses in Relapsed/Refractory B-Cell Lymphoma

April 21st 2021

The novel T-cell–engaging bispecific antibody glofitamab demonstrated encouraging clinical activity, with frequent and durable complete remissions, and a manageable toxicity profile in patients with predominantly refractory, aggressive B-cell lymphoma.